【24h】

Chromosomal instability determines taxane response

机译:染色体不稳定决定紫杉烷反应

获取原文
获取原文并翻译 | 示例
           

摘要

Microtubule-stabilizing (MTS) agents, such as taxanes, are important chemotherapeutics with a poorly understood mechanism of action. We identified a set of genes repressed in multiple cell lines in response to MTS agents and observed that these genes are overexpressed in tumors exhibiting chromosomal instability (CIN). Silencing 22/50 of these genes, many of which are involved in DNA repair, caused cancer cell death, suggesting that these genes are involved in the survival of aneuploid cells. Overexpression of these "CIN-survival" genes is associated with poor outcome in estrogen receptor-positive breast cancer and occurs frequently in basal-like and Her2-positive cases. In diploid cells, but not in chromosomally unstable cells, paclitaxel causes repression of CIN-survival genes, followed by cell death. In the OV01 ovarian cancer clinical trial, a high level of CIN was associated with taxane resistance but carboplatin sensitivity, indicating that CIN may determine MTS response in vivo. Thus, pretherapeutic assessment of CIN may optimize treatment stratification and clinical trial design using these agents.
机译:微管稳定剂(MTS),例如紫杉烷类,是重要的化学疗法,其作用机理尚不清楚。我们确定了一组响应MTS剂而在多种细胞系中被阻遏的基因,并观察到这些基因在表现出染色体不稳定性(CIN)的肿瘤中过表达。这些基因中有22/50个沉默,其中许多与DNA修复有关,导致癌细胞死亡,这表明这些基因与非整倍体细胞的存活有关。这些“ CIN-存活”基因的过表达与雌激素受体阳性乳腺癌的不良预后有关,并在基底样和Her2阳性病例中频繁发生。在二倍体细胞中,而非在染色体不稳定细胞中,紫杉醇引起CIN存活基因的抑制,随后细胞死亡。在OV01卵巢癌临床试验中,高水平的CIN与紫杉烷耐药性有关,但对卡铂敏感,表明CIN可能决定体内的MTS反应。因此,CIN的治疗前评估可以优化使用这些药物的治疗分层和临床试验设计。

著录项

  • 来源
  • 作者单位

    Cancer Research UK, London Research Institute, London WC2A 3PX, United Kingdom Royal Marsden Hospital, Department of Medicine, Sutton SM2 5PT,United Kingdom;

    Cancer Research UK, London Research Institute, London WC2A 3PX, United Kingdom;

    Cancer Research UK, London Research Institute, London WC2A 3PX, United Kingdom University of Applied Sciences Koblenz, RheinAhrCampus, 53424 Remagen, Germany;

    Center for Biological Sequence Analysis, Technical University of Denmark, DK-2800 Lyngby, Denmark;

    Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Cambridge CB2 ORE, United Kingdom Department of Oncology, University of Cambridge CB2 OXZ, United Kingdom;

    Cancer Research UK, London Research Institute, London WC2A 3PX, United Kingdom;

    Cancer Research UK, London Research Institute, London WC2A 3PX, United Kingdom;

    Cancer Research UK, London Research Institute, London WC2A 3PX, United Kingdom;

    University of Applied Sciences Koblenz, RheinAhrCampus, 53424 Remagen, Germany;

    University of Applied Sciences Koblenz, RheinAhrCampus, 53424 Remagen, Germany;

    TTP LabTech Ltd, Hertfordshire SG8 6EE, United Kingdom;

    Digital Genomics Inc. Seoul 120-749, Korea;

    Wenzhou Medical College, Zhejiang 32500, P.R. China;

    Cancer Research UK, London Research Institute, London WC2A 3PX, United Kingdom;

    Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892;

    University Hospital Schleswig-Holstein, Campus Luebeck, Department of Surgery, 23538 Luebeck, Germany;

    Karolinska Institutet, 5-171 76 Stockholm, Sweden;

    Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Cambridge CB2 ORE, United Kingdom Karolinska Institutet, 5-171 76 Stockholm, Sweden;

    Center for Biological Sequence Analysis, Technical University of Denmark, DK-2800 Lyngby, Denmark Children's Hospital Informatics Program, Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School, Boston, MA 02115;

  • 收录信息 美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    chemotherapy; drug resistance;

    机译:化学疗法耐药性;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号